[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulmonx Corp (LUNG)

Pulmonx Corp (LUNG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,467
  • Shares Outstanding, K 42,237
  • Annual Sales, $ 90,500 K
  • Annual Income, $ -54,000 K
  • EBIT $ -52 M
  • EBITDA $ -51 M
  • 60-Month Beta 0.18
  • Price/Sales 0.72
  • Price/Cash Flow N/A
  • Price/Book 1.42

Options Overview Details

View History
  • Implied Volatility 152.69% (+10.87%)
  • Historical Volatility 64.91%
  • IV Percentile 20%
  • IV Rank 10.90%
  • IV High 651.31% on 03/20/26
  • IV Low 91.70% on 06/23/25
  • Expected Move (DTE 24) 0.0170 (1.10%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 56
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 342
  • Open Int (30-Day) 3,214
  • Expected Range 1.5330 to 1.5670

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.28
  • Number of Estimates 2
  • High Estimate $-0.27
  • Low Estimate $-0.29
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) +26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +31.36%
on 04/30/26
1.6290 -4.85%
on 05/22/26
+0.2500 (+19.23%)
since 04/22/26
3-Month
1.1300 +37.17%
on 03/30/26
2.1600 -28.24%
on 03/06/26
+0.0450 (+2.99%)
since 02/20/26
52-Week
1.1300 +37.17%
on 03/30/26
3.8800 -60.05%
on 07/23/25
-1.5700 (-50.32%)
since 05/22/25

Most Recent Stories

More News
Pulmonx Reports First Quarter 2026 Financial Results

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today...

LUNG : 1.5500 (+0.65%)
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the...

LUNG : 1.5500 (+0.65%)
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it...

LUNG : 1.5500 (+0.65%)
Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today...

LUNG : 1.5500 (+0.65%)
Pulmonx Announces Closing of up to $60 Million Credit Facility

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today...

LUNG : 1.5500 (+0.65%)
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it...

LUNG : 1.5500 (+0.65%)
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today...

LUNG : 1.5500 (+0.65%)
Pulmonx Reports Third Quarter 2025 Financial Results

REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported...

LUNG : 1.5500 (+0.65%)
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive Officer Derrick Sung, former Pulmonx Chief Financial Officer,...

LUNG : 1.5500 (+0.65%)
Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced...

LUNG : 1.5500 (+0.65%)

Business Summary

Pulmonx Corporation is a medical technology company. It designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. Pulmonx Corporation is based in Redwood City, California.

See More

Key Turning Points

3rd Resistance Point 1.6950
2nd Resistance Point 1.6620
1st Resistance Point 1.6060
Last Price 1.5500
1st Support Level 1.5170
2nd Support Level 1.4840
3rd Support Level 1.4280

See More

52-Week High 3.8800
Fibonacci 61.8% 2.8295
Fibonacci 50% 2.5050
Fibonacci 38.2% 2.1805
Last Price 1.5500
52-Week Low 1.1300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.